NCT06043947

Brief Summary

This study aims to establish a holistic framework for continuous cancer survival surveillance in Russian regions with high-quality population-based cancer registry data. The data from the population-based cancer registries of the Northwestern regions of Russia will be used to assess net and cause-specific survival trends.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2023

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

September 11, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

September 21, 2023

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

May 1, 2025

Status Verified

April 1, 2025

Enrollment Period

1.4 years

First QC Date

September 11, 2023

Last Update Submit

April 28, 2025

Conditions

MelanomaBreast CancerOncologyColon CancerProstate CancerSurvivorshipLung CancerCervix Cancer

Keywords

Survivorship surveySurvivorship careOncologyMelanomaBreast cancerLung cancer

Outcome Measures

Primary Outcomes (2)

  • Net survival

    Net survival computed using Pohar-Perme method.

    From the date of diagnosis to the date of death (up to 10 years)

  • Cause-specific survival

    Rates calculated using Kaplan-Maier method.

    From the date of diagnosis to the date of death (up to 10 years)

Eligibility Criteria

Age0 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Cancer patient population, that were diagnosed and registered in regions covered by PBCR.

You may qualify if:

  • Men and women of any age
  • Data record meets IARC/IACR Tools for Cancer Registries requirements

You may not qualify if:

  • Severe patient data missing from a record

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

N. N. Petrov Research Institute of oncology

Saint Petersburg, 197758, Russia

Location

Related Publications (1)

  • Barchuk A, Tursun-Zade R, Belayev A, Moore M, Komarov Y, Moshina N, Anttila A, Nevalainen J, Auvinen A, Ryzhov A, Znaor A. Comparability and validity of cancer registry data in the northwest of Russia. Acta Oncol. 2021 Oct;60(10):1264-1271. doi: 10.1080/0284186X.2021.1967443. Epub 2021 Aug 23.

    PMID: 34424113BACKGROUND

MeSH Terms

Conditions

MelanomaBreast NeoplasmsNeoplasmsColonic NeoplasmsProstatic NeoplasmsLung NeoplasmsUterine Cervical Neoplasms

Condition Hierarchy (Ancestors)

Neuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasms, Nerve TissueNevi and MelanomasSkin NeoplasmsNeoplasms by SiteSkin DiseasesSkin and Connective Tissue DiseasesBreast DiseasesColorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesGenital Neoplasms, MaleUrogenital NeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital DiseasesRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesUterine NeoplasmsGenital Neoplasms, FemaleUterine Cervical DiseasesUterine DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy Complications

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 11, 2023

First Posted

September 21, 2023

Study Start

August 1, 2023

Primary Completion

December 31, 2024

Study Completion

December 31, 2025

Last Updated

May 1, 2025

Record last verified: 2025-04

Locations

RU(1)